Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor

Trial Profile

Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Anti-Cd7 CAR-NK cells (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Glioma; Liver cancer; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors PersonGen Biomedicine
  • Most Recent Events

    • 25 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top